Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency

Cytotherapy

Volumn 17, Issue 12, 2015, Pages 1675-1686

  Salem, Bahey ^a,c   Miner, Samantha ^a   Hensel, Nancy F ^a   Battiwalla, Minoo ^a   Keyvanfar, Keyvan ^a   Stroncek, David F ^b   Gee, Adrian P ^c   Hanley, Patrick J ^d   Bollard, Catherine M ^d   Ito, Sawa ^a   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Immunosuppression; K299; Mesenchymal stromal cells; Suppression potency assay

Indexed keywords

CD40 LIGAND; ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON;

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SUPPRESSION POTENCY ASSAY; BIOASSAY; BONE MARROW CELL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CYTOLOGY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PROCEDURES;

ANTIBODIES; ANTIGENS, CD28; ANTIGENS, CD3; BIOLOGICAL ASSAY; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS;

EID: 84947614477     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.08.008     Document Type: Article

References (31)

1. Owen R.D. Immunogenetic Consequences of Vascular Anastomoses between Bovine Twins. Science 1945, 102:400-401.
2. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172:603-606.
3. Silverstein A.M. Ontogeny of the Immune Response. Science 1964, 144:1423-1428.
4. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
5. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013, 13:739-752.
6. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
7. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
8. Wood K.J., Bushell A., Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012, 12:417-430.
9. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
10. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
11. Lund F.E., Randall T.D. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 2010, 10:236-247.
12. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
13. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
14. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
15. Martelli M.F., Di Ianni M., Ruggeri L., Falzetti F., Carotti A., Terenzi A., et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014, 124:638-644.
16. Bloom D.D., Centanni J.M., Bhatia N., Emler C.A., Drier D., Leverson G.E., et al. A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cytotherapy 2015, 17:140-151.
17. Wells A.D., Gudmundsdottir H., Turka L.A. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997, 100:3173-3183.
18. Galipeau J., Krampera M. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 2015, 17:125-127.
19. Chattopadhyay P.K., Yu J., Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005, 11:1113-1117.
20. Canavan J.B., Afzali B., Scotta C., Fazekasova H., Edozie F.C., Macdonald T.T., et al. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 2012, 119:e57-e66.
21. Ruitenberg J.J., Boyce C., Hingorani R., Putnam A., Ghanekar S.A. Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Methods 2011, 372:95-106.
22. Fischer P., Nacheva E., Mason D.Y., Sherrington P.D., Hoyle C., Hayhoe F.G., et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988, 72:234-240.
23. Wolke C., Tadje J., Bukowska A., Täger M., Bank U., Ittenson A., et al. Assigning the phenotype of a natural regulatory T-cell to the human T-cell line, KARPAS-299. Int J Mol Med 2006, 17:275-278.
24. Hanley P.J., Mei Z., Durett A.G., Cabreira-Harrison Mda G., Klis M., Li W., et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 2014, 16:1048-1058.
25. Martin-Manso G., Hanley P.J. Using the quantum cell expansion system for the automated expansion of clinical-grade bone marrow-derived human mesenchymal stromal cells. Methods Mol Biol 2015, 1283:53-63.
26. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
27. Lugli E., Gattinoni L., Roberto A., Mavilio D., Price D.A., Restifo N.P., et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 2013, 8:33-42.
28. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639-646.
29. Gosselin A., Monteiro P., Chomont N., Diaz-Griffero F., Said E.A., Fonseca S., et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 2010, 184:1604-1616.
30. Chinnadurai R., Copland I.B., Patel S.R., Galipeau J. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol 2014, 192:1491-1501.
31. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.